Biotech advocates call on the feds to strengthen industry incentives
Advocates press for support from Ottawa to help the domestic biotech industry grow.
Elaine Campbell, left, interim president of Innovative Medicines Canada, says the long-serving Scientific Research and Experimental Development tax credit offers such negligible benefits for certain pharmaceutical companies they don't even bothering reporting in Canada to ascertain it. However, Andrew Casey, president of BIOTECanada, called it 'hugely important' for the biotechnology industry. Photographs courtesy of Innovative Medicines Canada and BIOTECanada